

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Cardboard box}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Maropicord 10 mg/mL solution for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each ml contains  
Maropitant 10 mg  
(equivalent to maropitant citrate monohydrate 14.48 mg)

**3. PACKAGE SIZE**

20 ml

**4. TARGET SPECIES**

Dogs and cats.

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Subcutaneous or intravenous use.

**7. WITHDRAWAL PERIODS**

**8. EXPIRY DATE**

Exp. {mm/yyyy}  
Once broached, use within 28 days.  
Once broached, use by:

**9. SPECIAL STORAGE PRECAUTIONS**

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Accord Healthcare B.V.

**14. MARKETING AUTHORISATION NUMBERS**

UK(NI) Vm 42153/3005  
UK(GB) Vm 42153/5003

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING**  
**UNITS {Glass vial}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Maropicord

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Maropitant 10 mg/mL

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Once broached, use within 28 days

Once broached, use by \_\_\_\_\_

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Maropicord 10 mg/ml solution for injection for dogs and cats

#### **2. Composition**

Each ml contains

##### **Active substances:**

Maropitant 10 mg

*(equivalent to maropitant citrate monohydrate 14.48 mg)*

##### **Excipients:**

Metacresol                      3.3 mg

A clear, colourless to light yellow solution.

#### **3. Target species**

Dogs and cats.

#### **4. Indications for use**

##### **Dogs**

- For the treatment and prevention of nausea induced by chemotherapy.
- For the prevention of vomiting except that induced by motion sickness.
- For the treatment of vomiting, in combination with other supportive measures.
- For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the  $\mu$ -opiate receptor agonist morphine.

##### **Cats**

- For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
- For the treatment of vomiting, in combination with other supportive measures.

#### **5. Contraindications**

None.

## **6. Special warnings**

### Special warnings:

Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed.

Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.

The use of this veterinary medicinal product against vomiting due to motion sickness is not recommended.

### **Dogs:**

Although this veterinary medicinal product has been demonstrated to be effective in both the treatment and prevention of emesis induced by chemotherapy, it was found more efficacious if used preventively. Therefore, it is recommended to administer the antiemetic prior to administration of the chemotherapeutic agent.

### **Cats:**

The efficacy of this veterinary medicinal product in reduction of nausea was demonstrated in studies using a model (xylazine-induced nausea).

### Special precautions for safe use in the target species:

The safety of the veterinary medicinal product has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats. The responsible veterinarian should make a benefit-risk assessment before using this veterinary medicinal product in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating bitches and cats.

Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease.

This veterinary medicinal product should be used with caution in animals suffering from or with predisposition for heart diseases

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.

Wash hands after use. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Maropitant has been shown to be a potential eye irritant, and in the case of accidental eye exposure, flush the eyes with plenty of water and seek medical attention.

### Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

The veterinary medicinal product should not be used concomitantly with Ca- channel antagonists as this veterinary medicinal product has affinity to Ca- channels. Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.

Overdose:

Apart from transient reactions at the injection site following subcutaneous administration, this veterinary medicinal product was well tolerated in dogs and young cats injected daily with up to 5 mg/kg bodyweight (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration). No data have been presented on overdoses in adult cats.

Major incompatibilities:

This veterinary medicinal product must not be mixed with other veterinary medicinal products in the same syringe as its compatibility with other products has not been tested.

**7. Adverse events**

Dogs and cats:

Very common (>1 animal / 10 animals treated):
Injection site pain <sup>1,2</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Anaphylactic-type reaction (e.g. allergic oedema, urticaria, collapse NOS, dyspnoea, pale mucous membranes) Lethargy Neurological disorder (e.g. ataxia, convulsion, seizure, muscle tremor)

<sup>1</sup> When injected subcutaneously.

<sup>2</sup> A moderate to severe response can be observed in approximately one third of cats.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

**8. Dosage for each species, routes and method of administration**

For subcutaneous or intravenous use in dogs and cats.

This veterinary medicinal product should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight). Treatment may be repeated for up to five consecutive days.

Intravenous administration of the veterinary medicinal product should be given as a single bolus without mixing the veterinary medicinal product with any other fluids.

In dogs, this veterinary medicinal product can be used to treat or prevent vomiting once daily for up to 5 days.

### **9. Advice on correct administration**

To prevent vomiting, this veterinary medicinal product should be administered more than 1 hour in advance. The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy.

Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied. Injecting the veterinary medicinal product at refrigerated temperature may reduce pain at injection.

### **10. Withdrawal periods**

Not applicable.

### **11. Special storage precautions**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and on the vial after Exp.

The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: 28 days.

### **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems.

These measures should help to protect the environment.

### **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

### **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

UK(NI) Vm 42153/3005

UK(GB) Vm 42153/5003

Pack size:

Cardboard box with 1 x 20 ml vial.

### **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

### **16. Contact details**

Marketing authorisation holder and contact details to report suspected adverse events:

Accord Healthcare B.V  
Winthontlaan 200,  
P. O. Box 95,  
Utrecht,  
3526 KV,  
The Netherlands  
Telephone number: +44 (0) 208 901 3383

Manufacturer responsible for batch release:

Laboratori Fundació DAU  
Calle Lletra C De La Zona Franca 12-14, Poligono Industrial De La Zona Franca De  
Barcelona,  
Barcelona, 08040, Spain

### **17. Other information**

*Gavin Hall*

Approved: 05 March 2026